Predominant mutation of codon 41 of the [beta]-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol
Constitutive activation of the wnt-signaling pathway plays an important role during both human and rat colon carcinogenesis and can be brought through mutations in either the adenomatous polyposis coli or the [beta]-catenin gene. Mutations found in the [beta]-catenin gene typically affect one out of...
Gespeichert in:
Veröffentlicht in: | Carcinogenesis (New York) 2001-11, Vol.22 (11), p.1885 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Constitutive activation of the wnt-signaling pathway plays an important role during both human and rat colon carcinogenesis and can be brought through mutations in either the adenomatous polyposis coli or the [beta]-catenin gene. Mutations found in the [beta]-catenin gene typically affect one out of four regulatory phosphorylation sites near the N-terminus of the [beta]-catenin protein. Whereas in human colon cancers, however, the majority of [beta]-catenin mutations directly alter threonine 41 or serine 45; the [beta]-catenin mutations found in chemically induced rat colon tumors seemed to cluster around codon 33 instead. Unlike previous studies, that have used relatively short-term (2-5 weeks) treatment with one of the alkylating agents 1,2,-dimethylhydrazine (DMH) or azoxymethane, we have investigated the mutational spectrum of the [beta]-catenin gene in a panel of rat colon tumors induced by long-term (20 weeks) DMH-treatment. We detected [beta]-catenin mutations in 12 of 33 (36%) tumors. Interestingly, only one of the [beta]-catenin mutations found affected the previously implicated codon 33 cluster region (Asp32Asn), whereas 11 of 12 (>90%) mutations represented identical C[Right arrow]T transitions within codon 41 resulting in the common replacement of threonine by isoleucine. We propose a model in which codon 41 mutations bear higher oncogenic potential but are induced by DMH less frequently than mutations in the codon 33 cluster region. Consequently, only after sustained carcinogenic treatment, as is achieved in the long-term DMH-protocol, codon 41 mutations will be induced frequently enough to be present in all developing malignant lesions and, then, because of their higher oncogenic potential, these are selected for. |
---|---|
ISSN: | 0143-3334 1460-2180 |